Patterns of interventions for central venous catheter-associated deep vein thrombosis and outcomes in cancer patients

Abstract

Purpose

This letter evaluated the impact of different management strategies, specifically the presence or absence of therapeutic anticoagulation, on clinical outcomes for central venous catheter (CVC)-associated deep vein thrombosis (DVT) in cancer patients.

Methods

One-hundred ninety-eight adult cancer patients with a confirmed CVC-associated DVT diagnosis from February 2013 and February 2021 were included.

Results

Incidence of symptomatic recurrent venous thromboembolism (VTE) was similar between patients who received therapeutic anticoagulation and those who did not (14% vs 16%, p = 0.807). In addition, therapeutic anticoagulation did not significantly alter the incidence of grade 3 and above bleeding events despite most patients having hematologic malignancies (9% vs 8%, p = 0.826).

Conclusion and relevance

Therapeutic anticoagulation was not associated with a reduction in the incidence of recurrent VTE or increase the incidence of bleeding in adult cancer patients following a CVC-associated DVT diagnosis.

Keywords

Central line central venous catheter peripherally inserted central catheter port-a-cath Hickman catheter venous thromboembolism

Get full access to this article

View all access options for this article.

References

Geerts

. Central venous catheter-related thrombosis. Hematol Am Soc Hematol Educ Program 2014; 2014: 306–311.

Citla Sridhar

Abou-Ismail

Ahuja

. Central venous catheter-related thrombosis in children and adults. Thromb Res 2020; 187: 103–112.

Streiff

Holmstrom

Angelini

, et al. Cancer-associated venous thromboembolic disease, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2021; 19: 1181–1201.

Johannesdottir

Horváth-Puhó

Dekkers

, et al. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med 2013; 173: 743–752.

Farge

Frere

Connors

, et al. International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 2022; 23: e334–e347.

Falanga

Di Nisio

, et al. ESMO Guidelines Committee. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol 2023; 34: 452–467. Epub 2023 Jan 10.

Kearon

Akl

Comerota

, et al. Antithrombotic therapy for VTE disease: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College Of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e419S–e496S.

National Comprehensive Cancer Network. Cancer-Associated Venous Thromboembolic Disease (Version 1.2023 — March 28, 2023). https://www.nccn.org/professionals/physician_gls/pdf/vte.pdf. Accessed May 6, 2023.

Social Science Statistics. Chi-Square Test Calculator. Accessed December 2022. https://www.socscistatistics.com/tests/chisquare2/default2.aspx.

10.

Marin

Bull

Kinzie

, et al. Central catheter-associated deep vein thrombosis in cancer: clinical course, prophylaxis, treatment. BMJ Support Palliat Care 2021; 11: 371–380.

11.

Kovacs

Wells

Rodger

, et al. A prospective study of Apixaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients: catheter 3 [abstract]. Blood 2022; 140: 1245–1246. Abstract 517.

12.

Houghton

Billett

Gaddh

, et al. Risk of pulmonary emboli after removal of an upper extremity central catheter associated with a deep vein thrombosis. Blood Adv 2021; 5: 2807–2812.